

**Profiling of Bile Acids in Human Plasma
Using Triple Quadrupole Mass Spectrometer**

Bile acids are produced in the liver by the catabolism of cholesterol, and synthesized to primary bile acids by conjugating with taurine or glycine. Some primary bile acids are modified by intestinal bacteria to produce the secondary bile acids.

These bile acids promote lipid absorption as a surfactant and inhibit metabolic pathways.

For early diagnosis or functional evaluation of hepatic diseases, blood enzyme activity tests (such as those for ALT and AST) and total bile acids test are widely used. Although the total bile acids test allows us to ascertain that a decrease in hepatic functions has occurred, additional tests are required for disease identification. Therefore, to simultaneously identify diseases, such as bile acid metabolic disorder, simultaneous analysis of the primary and other bile acids is required in addition to the total bile acids test.

For many bile acids, it is difficult to generate fragment ions by a triple quadrupole mass spectrometer because of their structures, and these bile acids should be completely separated under optimized LC conditions to facilitate accurate qualitative/quantitative analysis. Therefore, for accurate determination and quantification of these bile acids, good chromatographic separation is required.

This report introduces an example of analysis of 28 bile acids and 10 internal standards in human plasma using "LC/MS/MS Method Package for Bile Acids," a method in which the conditions for liquid chromatography and triple quadrupole mass spectrometry have been optimized.

M. Levi, A. Kunisawa

■ Pretreatment

The human plasma sample was collected from an anonymous healthy subject. Fifty μL of plasma was mixed with 10 μL of internal standard solution (10 $\mu\text{mol/L}$ in methanol). This was followed by the addition of 30 μL of aqueous hydrochloric acid (1 mol/L), and then 1000 μL of acetonitrile. After shaking by a vortex mixer for approximately one minute, the sample was centrifuged at 14000 G for 15 minutes. Then, 850 μL of supernatant was transferred to another micro tube, and evaporated to dryness with a vacuum evaporator. Finally, the solution re-dissolved with 100 μL of methanol was sonicated for 10 minutes, centrifuged at 14000 G for 15 minutes, and transferred to a vial with a glass insert for analysis.



Fig. 1 LC/MS/MS Method Package for Bile Acids and LCMS™-8060 System




Fig. 2 Structures of Representative Bile Acids

Analytical Conditions

The pretreated plasma was analyzed under the conditions shown in Table 1. In the analysis, "LC/MS/MS Method Package for Bile Acids *1" and LCMS-8060 were used. For quantitative analysis, the stable isotope dilution method was used.

Using this method, 28 compounds consisting of the major primary bile acids, secondary bile acids and their conjugates can be simultaneously analyzed in only 17 minutes. Furthermore, the optimized MS/MS conditions for bile acids and their conjugates are applied, and up to three MRM transitions are set up. Ten stable isotopes for which the MS/MS conditions have been optimized are designated as the internal standards to obtain high quantitative accuracy.

Table 1 Analytical Conditions

UHPLC (Nexera™ X2 system)	
Column	: Shim-pack™ G-BA C18 ^{*2}
Mobile phase	: A) Acetic acid in water B) Acetonitrile/Methanol
Mode	: Gradient elution
Flow rate	: 0.3 mL/min
Column temp.	: 40 °C
MS (LCMS™-8060)	
Ionization	: ESI (negative mode)
Mode	: MRM
Nebulizing gas flow	: 2.0 L/min
Drying gas flow	: 10.0 L/min
Heating gas flow	: 10.0 L/min
DL temp.	: 250 °C
Block heater temp.	: 400 °C
Interface temp.	: 300 °C

*1: P/N S225-38610-91

*2: P/N 227-30815-01

Results of Analysis

As shown in Table 2, a total of 15 bile acids were detected from human plasma. The detected compounds consist of 1 primary bile acid, 3 secondary bile acids, 6 taurine-conjugated and 5 glycine-conjugated secondary bile acids. Fig. 3 shows the chromatogram of bile acids. Fig. 4 shows the concentrations of bile acids calculated based on the quantitative results of these compounds.

Table 2 Compounds Detected by the Analysis of Bile Acids in Human Plasma

Compound	Abbreviated name	Concentration (pmol/mL)
Tauro-β-muricholic acid	TβMCA	4.28
Tauroursodeoxycholic acid	TUDCA	3.86
Taurocholic acid	TCA	18.8
Taurochenodeoxycholic acid	TCDC	82.6
Taurodeoxycholic acid	TDCA	41.1
Taurolithocholic acid	TLCA	8.58
Glycocholic acid	GCA	116
Glyoursodeoxycholic acid	GUJCA	241
Glyochenodeoxycholic acid	GCDC	792
Cholic acid	CA	131
Glycodeoxycholic acid	GDCA	135
Ursodeoxycholic acid	UDCA	58.7
Chenodeoxycholic acid	CDCA	334
Deoxycholic acid	DCA	599
Glycolithocholic acid	GLCA	119




Fig. 3 Mass Chromatogram Obtained by the Analysis of Bile Acids in Human Plasma




Fig. 4 Concentrations Calculated on the Analysis Results of Bile Acids in Human Plasma (Graph)

Conclusion

As mentioned above, the use of LC-MS/MS and "LC/MS/MS Method Package for Bile Acids," which enables highly sensitive and comprehensive analysis, allows quick detection and quantification of bile acids in human plasma samples. Therefore, this method is expected to be used for intestinal bacterial studies and pathological studies in various phases of clinical research.

<Acknowledgment>

This Application News was prepared with great assistance of Professor Takeshi Bamba and Associate Professor Yoshihiro Izumi of Research Center for Transomics Medicine, Medical Institute of Bioregulation, Kyushu University.

LCMS, LabSolutions, Nexera and Shim-pack are trademarks of Shimadzu Corporation in Japan and/or other countries.

First Edition: Sep. 2020



Shimadzu Corporation

www.shimadzu.com/an/

For Research Use Only. Not for use in diagnostic procedure.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Shimadzu disclaims any proprietary interest in trademarks and trade names used in this publication other than its own. See <http://www.shimadzu.com/about/trademarks/index.html> for details.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.

© Shimadzu Corporation, 2020